5 results match your criteria: "Tsukuba University Faculty of Medicine[Affiliation]"
Tuberk Toraks
September 2024
Divisions of Respiratory Medicine and Thoracic Surgery, Mito Medical Center, Mito Kyodo General Hospital, Tsukuba University Faculty of Medicine, Mito, Japan.
Tuberk Toraks
March 2022
Division of Respiratory Medicine, Mito Medical Center-Mito Kyodo General Hospital, Tsukuba University Faculty of Medicine, Mito, Japan.
Cells
November 2021
Glycometabolic Biochemistry Laboratory, RIKEN Cluster for Pioneering Research (CPR), 2-1 Hirosawa, Wako 351-0198, Japan.
Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations. Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern. Whole-exome sequencing showed that both patients were homozygous for a novel pathogenic variant of (NM_016219.
View Article and Find Full Text PDFCancer
October 2016
Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Background: Whether biochemical recurrence (BR) is a significant predictive factor of mortality after definitive radiation therapy for prostate cancer remains unknown. The aim of the current study was to investigate the relation between BR and overall mortality (OAM) in high-risk prostate cancer patients who were treated with carbon-ion radiotherapy (CIRT) and had long-term follow-up in 2 prospective trials.
Methods: In the 2 phase 2 clinical trials, which involved 466 prostate cancer patients who received 63.
Int J Urol
April 2012
Department of Radiation Oncology, Tsukuba University Faculty of Medicine, Tsukuba, Ibaraki, Japan.
In 1994, carbon-ion radiotherapy was started at the National Institute of Radiological Sciences using the Heavy-Ion Medical Accelerator in Chiba. Between June 1995 and March 2000, two phase I/II dose escalation studies (protocols 9402 and 9703) of hypofractionated carbon-ion radiotherapy for both early- and advance-stage prostate cancer patients had been carried out to establish radiotherapy technique and to determine the optimal radiation dose. To validate the feasibility and efficacy of hypofractionated carbon-ion radiotherapy, a phase II study (9904) was initiated in April 2000 using the shrinking field technique and the recommended dose fractionation (66 gray equivalents in 20 fractions over 5 weeks) obtained from the phase I/II studies, and was successfully completed in October 2003.
View Article and Find Full Text PDF